false
Catalog
Addiction is a Brain Disease
Recording
Recording
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
This presentation from the Opioid Response Network, funded by SAMHSA, focuses on addressing opioid and stimulant use disorders, particularly in justice settings. The training emphasizes addiction as a chronic brain disease, highlighting how substances impact brain function and lead to compulsive drug-seeking behavior. Opioid-related changes in brain chemistry, such as dopamine release and receptor engagement, affect judgment and pleasure perception, altering behavior and reinforcing addiction.<br /><br />The recommended treatment involves a medical model using FDA-approved medications like methadone, buprenorphine, and naltrexone, which are more effective than abstinence alone. These medications stabilize brain chemistry, reducing withdrawal symptoms and eliminating drug cravings, thereby supporting recovery.<br /><br />Special attention is given to justice-involved populations, where substance use and criminal behavior overlap significantly. Effective screening and treatment within this group can reduce recidivism and improve public health outcomes. The training stresses the importance of integrating medication-based treatment into correctional settings to improve post-release outcomes and prevent relapse and overdose.<br /><br />Finally, the session concludes with an appeal for feedback to improve future training, underscoring the ongoing efforts to educate and provide resources for combating substance use disorders.
Keywords
Opioid Response Network
SAMHSA
opioid use disorder
stimulant use disorder
justice settings
addiction treatment
methadone
buprenorphine
naltrexone
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.
Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 and grant no. 1H79TI085588 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
PCSS-MOUD
PCSS-MOUD.org
pcss@aaap.org
8-Hour DEA Training Inquiries, email
PCSS-MOUD
.
ORN
opioidresponsenetwork.org
×
Please select your language
1
English